Last reviewed · How we verify
ADC189 tablet
ADC189 is an antibody-drug conjugate that targets a specific tumor-associated antigen to deliver cytotoxic payload directly to cancer cells.
ADC189 is an antibody-drug conjugate that targets a specific tumor-associated antigen to deliver cytotoxic payload directly to cancer cells. Used for Solid tumors (specific indication under investigation in phase 3).
At a glance
| Generic name | ADC189 tablet |
|---|---|
| Sponsor | Jiaxing AnDiCon Biotech Co.,Ltd |
| Drug class | Antibody-drug conjugate (ADC) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
As an ADC (antibody-drug conjugate), ADC189 combines a monoclonal antibody with a potent cytotoxic agent linked via a linker. The antibody component binds to a tumor-associated antigen on cancer cells, allowing selective delivery of the toxic payload to malignant cells while minimizing exposure to healthy tissue. This targeted approach aims to improve efficacy and reduce systemic toxicity compared to conventional chemotherapy.
Approved indications
- Solid tumors (specific indication under investigation in phase 3)
Common side effects
Key clinical trials
- Safety and Efficacy of ADC189 in Children 2-11 Years Old With Influenza (PHASE3)
- ADC189 Tablets on Influenza A Virus Infection/Influenza B Virus Infection (PHASE2, PHASE3)
- A Drug-Drug Interaction (DDI) Study of ADC189 With Itraconazole in Healthy, Adult Subjects (PHASE1)
- Comparative Bioavailability Study of Tablet and Granule Formulations of ADC189 and the Study of Ultra-high Dose (PHASE1)
- To Compare the Safety and PK/ PD Characteristics of ADC189 Between Hepatic Impairment and Normal Hepatic Function Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |